Cite
HARVARD Citation
Catenacci, D. et al. (n.d.). 662PBiomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). Annals of oncology. p. . [Online].